louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06211907: Small Macular Holes Treated With Air
Official title: Small Macular Holes Treated With Air: A Prospective Randomized Controlled Multicenter Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Macular Holes
Lead sponsor: Helse Stavanger HF
Sponsor class: OTHER_GOV
Collaborators: name: Haukeland University Hospital
name: St. Olavs Hospital, Trondheim, Norway
name: Oslo University Hospital, Oslo, Norway
name: University Hospital of Northern Norway, Tromsø, Norway
name: University of Stavanger
name: Royal Liverpool University Hospital
name: Bangor University, Qwynedd, UK
name: McGill University
name: University Hospital Complex of Santiago de Compostela, Galicia, Spain
First posted: 2024-01-18
Enrollment: 132
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Non-inferiority Trial
Primary purpose: TREATMENT

Brief summary: Non-inferiority trial comparing intraocular air and gas tamponade for closure of macular holes.


Eligibility criteria: Inclusion Criteria:

* Primary MH ≤250 μm
* MH duration ≤12 months
* No previous vitreoretinal surgery in study eye
* Ability to sign informed consent
* Signed informed consent
* Age ˃18 years

Exclusion Criteria:

* Previous vitreoretinal surgery in study eye
* Secondary MH caused by other conditions than vitreomacular traction
* Myopic MH, i.e., excessive myopia (more than -6 dioptres)
* Traumatic MH
* MH secondary to retinal detachment or other retinal diseases
* Previously participation in this study

Primary outcomes:
measure: Macular hole closure after single surgery
timeFrame: 4 weeks
Secondary outcomes:
measure: Change in outcome of patient well-being
timeFrame: 4 weeks and 4 months
measure: Change in visual acuity i ETDRS lines
timeFrame: 4 weeks and 4 months
Other outcomes:
Locations:
city: Thessaly
country: Greece
facility: Department of Ophthalmology, University of Thessaly
city: Stavanger
country: Norway
facility: Stavanger University Hospital
state: Rogaland
city: Tromsø
country: Norway
facility: University Hospital of Northern Norway
state: Troms
city: Trondheim
country: Norway
facility: St. Olavs University Hospital
state: Tronderlag
city: Bergen
country: Norway
facility: Haukeland University Hospital
state: Vestland
city: Oslo
country: Norway
facility: Oslo University Hospital
city: Santiago De Compostela
country: Spain
facility: Clinical Universitary Hospital of Santiago
state: La Coruna
Study officials:
References:
Clinical trial NCT05779007: Dose Reduction and Discontinuation With Anti-Fibrotic Medications
Official title: Assessment of the Dose Reduction and Discontinuation Associated With Anti-Fibrotic Medications in Patients With Idiopathic Pulmonary Fibrosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Idiopathic Pulmonary Fibrosis
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2023-03-22
Enrollment: 2778
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with idiopathic pulmonary fibrosis (IPF) who initiated either pirfenidone or nintedanib between October 2014 and September 2021.

Brief summary: The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.


Eligibility criteria: Inclusion Criteria:

* Presence of at least one pirfenidone or nintedanib prescription during the identification period (0/01/2014 to 09/30/2021; the date of first prescription for pirfenidone/nintedanib is the index date)
* Evidence of IPF: patient with at least one inpatient or two outpatient claims (\>14 days apart) with a diagnosis code for IPF during the study period (10/01/2013 to 09/30/2022)
* At least 18 years old at the index date
* Have at least 12 months of continuous enrollment in the health plan during pre-index period, and at least 6 months of continuous enrollment in post-index period

Exclusion Criteria:

* Any history of lung transplant during the 12-months pre-index/baseline period
* Any claims for a skilled nursing facility, a long-term care facility or hospice care during the 12-month pre-index period
* Evidence of non-IPF chronic fibrosis Interstitial Lung Disease (ILD) or connective tissue diseases during the 12-months pre-index period. The following conditions will be excluded: autoimmune, or connective tissue diseases (i.e., rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), dermatopolymyositis, systemic sclerosis, Sjogren's syndrome, and mixed connective tissue disease (CTD), sarcoidosis, and hypersensitivity pneumonitis).
* Missing demographic information (i.e., age or sex)

Primary outcomes:
measure: Incidence of dose reduction and/or temporary dose reduction
timeFrame: up to 12 months
Secondary outcomes:
measure: Drug discontinuation
timeFrame: up to 12 months
Other outcomes:
Locations:
city: Ridgefield
country: United States
facility: Boehringer Ingelheim
state: Connecticut
Study officials:
References:
Clinical trial NCT02136407: Seasonal Variations in Serum 25-hydroxy Vitamin-D Levels in a Swedish Cohort
Official title: Seasonal Variations in Serum 25-hydroxy Vitamin-D Levels in a Swedish Cohort
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Vitamin-D Insufficiency
Keywords: Vitamin D
vitamin D deficiency
parathyroid hormone
Lead sponsor: Sahlgrenska University Hospital
Sponsor class: OTHER
First posted: 2014-05-13
Enrollment: 615
Sex: ALL
Minimum age (years): 16
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Blood donors

Brief summary: The purpose of this study was to study seasonal inter-individual and intra-individual variations in S-25(OH)D and to explore parameters associated with S-25-OHD in healthy Swedish adults.

Detailed description: Serum was collected during 12 months and analysed for 25(OH)D in 540 healthy blood donors. The blood donors answered questionnaires concerning vitamin D supplements, smoking, physical activity, sunbed use and holidays in sunny locations. Repeated serum samples were also collected from thrombocyte donors to study the intra-individual variations in S-25(OH)D.

Eligibility criteria: Inclusion Criteria:

* healthy at the time of donating blood

Exclusion Criteria:

* unhealthy

Primary outcomes:
measure: Inter-individual and intra-individual varations in serum 25-hydroxy vitamin-D during different seasons.
timeFrame: Group1:Blood donors, single test, 25(OH)vit D at inclusion . Group 2: thrombocyte donors: multiple tests, serum 25(OH)vit D during 8 months.
Secondary outcomes:
Other outcomes:
Locations:
city: Gothenburg
country: Sweden
facility: Sahlgrenska University Hospital
Study officials:
References:
Clinical trial NCT04571307: Cryotherapy in Breast B3 Lesions
Official title: Pilot Study on the Feasibility of Cryotherapy as an Alternative Treatment for Phyllodes Tumors/Breast Fibroepithelial Lesions (FELs) Needing Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Breast Disease
Phyllodes Breast Tumor
Lead sponsor: KK Women's and Children's Hospital
Sponsor class: OTHER_GOV
First posted: 2020-10-01
Enrollment: 12
Sex: FEMALE
Minimum age (years): 21
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To determine the feasibility of cryotherapy for B3 fibroepithelial lesions


Eligibility criteria: Inclusion Criteria:

* lesion seen on ultrasound
* core biopsy revealed FEL of B3
* lesion \</+3.5cm
* keen for cryotherapy instead of surgery
* has other breast lesions for followup

Exclusion Criteria:

* cancer patients
* patients with bleeding diathesis
* lesions causing visible breast deformity

Primary outcomes:
measure: recurrence of the lesion
timeFrame: 2 years from procedure
measure: breast cosmetic outcome
timeFrame: at 1 year post procedure
measure: pain score
timeFrame: immediate post procedure
measure: pain score
timeFrame: at 2 weeks post procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: KK Women's and Children's Hospital
Study officials:
affiliation: KK Women's and Children's Hospital
name: Geok hoon lim
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03792607: Network-based Approach in Type 2 Diabetes and Its Cardiovascular Risk
Official title: Perturbation of Interactome Through Micro-RNA And Methylome Analyses In Diabetes Endophenotypes: the PIRAMIDE Study Design
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Type 2 Diabetes Mellitus
Cardiovascular Diseases
Keywords: Network medicine
Epigenetics
Diabetes
Cardiovascular risk
Lead sponsor: University of Campania Luigi Vanvitelli
Sponsor class: OTHER
First posted: 2019-01-03
Enrollment: 35
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: We will enroll 35 men and women 50 years or older with diagnosis of T2D and 35 sex and age-matched controls. Population study will be recruited at the Department of Medical, Surgical, Neurological, Metabolic and Geriatric Sciences of University della Campania "Luigi Vanvitelli".

Brief summary: PIRAMIDE study design will test the hypothesis that simultaneous interactions between DNA methylation and microRNAs may hit T2D candidate genes and predict the development of T2D-related cardiovascular complications.


Eligibility criteria: Exclusion Criteria:

* Clinical Diagnosis of Type 2 Diabetes. In according to current guidelines, diabetes is diagnosed by evidence of impairing fast glucose (IFG) \> 7.0 mmol/L (\>125 mg/dl), post prandial glycemia \> 11.1 mmol/L (\>200 mg/dl), and evidence of glycated hemoglobin (HbA1c) \> 6.6%. Clinical and demographic characteristics of study population will be avaiable from datasets generated by physicians.
* Clinical Diagnosis of macrovascular dysfunction.

Exclusion Criteria:

• Patients with known history of cancer, malignancy disorders, active infections, and chronic or immune-mediated diseases.

Primary outcomes:
measure: DNA methylation status both of CD4+ and CD8+ cells
timeFrame: 3 Months
measure: Bioinformatics analysis to predict putative novel T2D candidate genes
timeFrame: 6 Months
measure: RNA sequencing analysis both in CD4+ and CD8+ cells
timeFrame: 3 Months
Secondary outcomes:
measure: ROC curves to evaluate putative DNA methylation/microRNA interactions as prognostic biomarkers of cardiovascular dysfunction in T2D patients
timeFrame: 12 Months
Other outcomes:
Locations:
city: Naples
country: Italy
facility: Università della Campania Luigi Vanvitelli
Study officials:
affiliation: Clinical Department of Internal Medicine and Specialistics
name: Giuditta Benincasa, MSc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Benincasa G, Franzese M, Schiano C, Marfella R, Miceli M, Infante T, Sardu C, Zanfardino M, Affinito O, Mansueto G, Sommese L, Nicoletti GF, Salvatore M, Paolisso G, Napoli C. DNA methylation profiling of CD04+/CD08+ T cells reveals pathogenic mechanisms in increasing hyperglycemia: PIRAMIDE pilot study. Ann Med Surg (Lond). 2020 Oct 20;60:218-226. doi: 10.1016/j.amsu.2020.10.016. eCollection 2020 Dec.
Clinical trial NCT01287507: Lactoferrin Prophylaxis in VLBW and Regulator T-cells
Official title: Oral Lactoferrin Prophylaxis to Prevent Sepsis and Necrotising Enterocolitis of Very Low Birth Weight Neonates in Neonatal Intensive Care Unit and Effect on T-regulatory Cells.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Late Onset Neonatal Sepsis
Necrotising Enterocolitis
Very Low Birth Weight Infants
Keywords: VLBW, NEC, Late onset sepsis
Lead sponsor: Ankara University
Sponsor class: OTHER
First posted: 2011-02-01
Enrollment: 60
Sex: ALL
Minimum age (years): 15
Maximum age (years): 1
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of the study is to evaluate whether oral administration of 200 mg/day lactoferrin (LF) to very low birth weight infants reduces late onset sepsis and necrotising enterocolitis and the effect of LF on regulatory T cells.


Eligibility criteria: Inclusion Criteria:

* Inborn infants
* Gestational age \< 32 weeks
* Birth weight \< 1500 g
* Parental consent

Exclusion Criteria:

* Congenital abnormalities
* Severe perinatal asphyxia

Primary outcomes:
measure: late onset sepsis
timeFrame: from birth to discharge from NICU
measure: Necrotising enterocolitis
timeFrame: from birth to discharge from NICU
measure: Effect on T regulatory cells
timeFrame: at discharge
Secondary outcomes:
measure: Safety of lactoferrin in VLBW infants
timeFrame: during the oral use of lactoferrin
measure: duration of hospitalization
timeFrame: from birth to discharge from neonatal intensive care unit
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara University School of Medicine Department of Pediatrics, NICU
Study officials:
affiliation: Anlara University Chief of Neonatology
name: Saadet Arsan, Prof
role: STUDY_CHAIR
References:
Clinical trial NCT01467388: Efficacy of Selective Laser Trabeculoplasty in Pseudophakic Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Glaucoma
Ocular Hypertension
Keywords: patients with glaucoma or ocular hypertension
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2011-11-08
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: glaucoma patients

Brief summary: Retrospective analysis of efficacy of selective laser trabeculoplasty in pseudophakic patients compared to phakic patients is performed.

Inclusion criterion are patients with glaucoma or ocular hypertension who underwent treatment with selective laser trabeculoplasty due to insufficient control of intraocular pressure during their routine treatment at the University Hospital Zurich / Division of Ophthalmology.


Eligibility criteria: Inclusion criteria:

* Patients with glaucoma or ocular hypertension who underwent selective laser trabeculoplasty.

Exclusion criteria:

* Optic neuropathy other than glaucoma

Primary outcomes:
measure: IOP
timeFrame: t0
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich, Ophthalmic Clinic
state: ZH
Study officials:
affiliation: UniversitaetsSpital Zuerich
name: 01 Studienregister MasterAdmins
role: STUDY_DIRECTOR
affiliation: University Hospital Zurich, Ophtalmic Clinic
name: Jens Funk, Professor, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00284388: Incorporation of Muscle Qualities in Biomechanical Models of the Upper Limbs
Official title: Incorporation of Muscle Qualities in Biomechanical Models of the Upper Limbs
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Shoulder Prosthesis
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2006-01-31
Enrollment: 0
Sex: ALL
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Development of a non-invasive method for the determination of the position of optimal muscle length in the different muscles of the shoulder.

Analysis of the adaptation of the muscle to a new optimal length in patients with a shoulder prosthesis.


Eligibility criteria: Inclusion Criteria:

* Shoulder prosthesis

Exclusion Criteria:

-

Primary outcomes:
measure: Measurement of the optimal length of the muscles of the shoulder
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University Hospital, Ghent
name: Rene Verdonk, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02873988: Regeneration of Bronchial Epithelium During Chronic Obstructive Pulmonary Disease
Official title: Regeneration of Bronchial Epithelium During Chronic Obstructive Pulmonary Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COPD
Lead sponsor: CHU de Reims
Sponsor class: OTHER
First posted: 2016-08-22
Enrollment: 25
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients scheduled for lung resection for cancer

Brief summary: Airway epithelium integrity is essential to maintain its role of mechanical and functional barrier. Recurrent epithelial injuries require a complex mechanism of repair to restore its integrity. In chronic obstructive pulmonary disease (COPD), an abnormal airway epithelial repair may participate in airway remodelling. The objective was to determine if airway epithelial wound repair of airway epithelium is abnormal in COPD.

Detailed description: Patients scheduled for lung resection were prospectively recruited. Demographic, clinical data and pulmonary function tests results were recorded. Emphysema was visually scored and histological remodelling features were noted. Primary bronchial epithelial cells (BEC) were extracted and cultured for wound closure assay. The investigators determined the mean speed of wound closure (MSWC) and cell proliferation index, matrix metalloprotease (MMP)-2, MMP-9 and cytokines levels in supernatants of BEC 18 hours after cell wounding. In a subset of patients, bronchiolar epithelial cells were also cultured for wound closure assay for MSWC analyze.

Eligibility criteria: Inclusion Criteria:

6 Patients scheduled for lung resection for cancer

Exclusion Criteria:

* Patients with asthma, cystic fibrosis, bronchiectasis or pulmonary fibrosis were excluded

Primary outcomes:
measure: Mean speed of wound closure (MSWC) of wounded bronchial epithelial cell culture obtained from COPD and control patients
timeFrame: hour 18
Secondary outcomes:
measure: Cell proliferation index in supernatants of bronchial epithelial cells 18 hours after cell wounding.
timeFrame: hour 18
measure: Matrix metalloprotease (MMP)-2 level in supernatants of bronchial epithelial cells 18 hours after cell wounding.
timeFrame: hour 18
measure: Matrix metalloprotease (MMP)-9 level in supernatants of bronchial epithelial cells 18 hours after cell wounding.
timeFrame: hour 18
measure: Cytokines levels in supernatants of bronchial epithelial cells 18 hours after cell wounding.
timeFrame: hour 18
Other outcomes:
Locations:
city: Reims
country: France
facility: Chu de Reims
Study officials:
References:
citation: Perotin JM, Adam D, Vella-Boucaud J, Delepine G, Sandu S, Jonvel AC, Prevost A, Berthiot G, Pison C, Lebargy F, Birembaut P, Coraux C, Deslee G. Delay of airway epithelial wound repair in COPD is associated with airflow obstruction severity. Respir Res. 2014 Nov 27;15(1):151. doi: 10.1186/s12931-014-0151-9.
Clinical trial NCT06409507: Research and Application for New Clinical Diagnosis and Treatment System for HBV Related HCC Liver Transplantation
Official title: The Impact of FKBP12 on the Prognosis and Sirolimus Administration in Liver Transplantation Recipients With Hepatocellular Carcinoma: A Single-center Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatocellular Carcinoma
Liver Transplantation
Prognosis
Lead sponsor: First People's Hospital of Hangzhou
Sponsor class: OTHER
First posted: 2024-05-10
Enrollment: 178
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Deceased donor LT surgery was performed in all recipients at our center between January 1, 2015 and January 1, 2021. China Liver Transplant Registry database (http://www.cltr.org) was used to obtain clinical information about patients, which included age, gender, pathological characteristics, pre-LT alpha-fetoprotein (AFP), loco-regional therapy (including transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA)) before LT, model for end-stage liver disease (MELD) score, Child-Pugh score, hepatitis B virus status, sirolimus administration, date of surgery, recurrence, last follow up, and death. LT recipients were required for a follow-up examination every 3 months.

Brief summary: The study evaluated the protein expression levels of FK506-binding protein 12 (FKBP12) in hepatocellular carcinoma (HCC) and paracancerous tissues using immunohistochemistry (IHC). This study aimed to determine the role of FKBP12 in the outcome of liver transplantation recipients with HCC, especially those exceeding the Milan criteria. In addition, we explored how sirolimus administration affected LT recipients'prognosis depending on different FKBP12 expression, aiming to provide some advice for clinical sirolimus application after LT.


Eligibility criteria: Inclusion Criteria:

* (1) pathologically confirmed HCC (2) full post-LT follow-up record

Exclusion Criteria:

* (1)sirolimus treatment less than 30 days or after tumor recurrence (2)died within 90 days (3)underwent multiple-organ transplantation

Primary outcomes:
measure: Overall survival
timeFrame: 2015.1.1-2021.1.1
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06091007: Magnesium Citrate Supplementation on Hand Grip Strength
Official title: The Effects of Magnesium Citrate Supplementation on Hand Grip Strength: A Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hand Grasp
Keywords: hand grip magnesium citrate
Lead sponsor: Loma Linda University
Sponsor class: OTHER
First posted: 2023-10-19
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Group 1: participants take 200 mg of magnesium citrate daily for 4 weeks. Group 2: participants take 400 mg of magnesium citrate daily for 4 weeks.
Primary purpose: OTHER

Brief summary: The purpose of this research study is to determine the effectiveness of magnesium on handgrip strength using the more bioavailable magnesium citrate.

Detailed description: In this single-blind, randomized trial, participants will take a daily dose of either 200 or 400 milligrams of magnesium citrate supplement for four weeks, perform three separate handgrip strength tests using a dynamometer, complete a demographics questionnaire, a physical activity questionnaire, and a compliance log.

Eligibility criteria: Inclusion Criteria:

* Generally healthy community adults
* Individuals age 18 and over
* Male and female participants

Exclusion Criteria:

* Individuals currently on magnesium supplements
* Individuals currently on a multivitamin supplement
* Individuals who currently suffer from hand pain or hand injury
* Individuals who currently suffer from arthritis in their hands
* Individuals suffering from a gastrointestinal disorder complicated by diarrhea, nausea, or abdominal cramping

Primary outcomes:
measure: Hand grip strength
timeFrame: change between baseline and 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Loma Linda
country: United States
facility: Loma Linda University
state: California
Study officials:
affiliation: Loma Linda University
name: Kyndra Woosley, MS
role: PRINCIPAL_INVESTIGATOR
References: